A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

Alzheimer's disease (AD ... with a stabilization of the disease in a proportion of patients with mild AD after 3 years of treatment. Tramiprosate is being investigated in two pivotal 18-month ...

Researchers challenge everything we know about Alzheimer's disease with shocking new findings about amyloid beta protein's ...

Anavex Life Sciences shares were up 7% to $11.25 after the company said it saw positive trial results for its oral blarcamesine for the treatment of early Alzheimer's disease. The clinical-stage ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Impairment of autophagy precedes both amyloid beta and tau tangles, and ...

(“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease ...

Once daily oral administration of blarcamesine meaningfully slowed clinical decline in early Alzheimer's disease ... a novel treatment that could be complementary or an alternative to injectable ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...